1 |
Abed Y, Fage C, Checkmahomed L, Venable M, Boivin G. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice. Antiviral Research 2020;179:104807. [DOI: 10.1016/j.antiviral.2020.104807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
2 |
Abed Y, Fage C, Checkmahomed L, Begin G, Carbonneau J, Lague P, Boivin G. The Val430Ile neuraminidase (NA) substitution, identified in influenza B virus isolates, impacts the catalytic 116Arg residue causing reduced susceptibility to NA inhibitors. Antiviral Res 2019;170:104561. [PMID: 31323237 DOI: 10.1016/j.antiviral.2019.104561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
3 |
Pascua PNQ, Marathe BM, Bisen S, Webby RJ, Govorkova EA. Influenza B viruses from different genetic backgrounds are variably impaired by neuraminidase inhibitor resistance-associated substitutions. Antiviral Res 2020;173:104669. [PMID: 31790712 DOI: 10.1016/j.antiviral.2019.104669] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
4 |
Kodiyanplakkal RPL, Laplante JM, Westblade LF, van Besien K, Salvatore M, St George K. Detection and Characterization of Influenza B Virus With Reduced Neuraminidase Susceptibility in a Stem Cell Transplant Recipient. Open Forum Infect Dis 2019;6:ofz493. [PMID: 32128335 DOI: 10.1093/ofid/ofz493] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
5 |
Cardenas-Garcia S, Caceres CJ, Rajao D, Perez DR. Reverse genetics for influenza B viruses and recent advances in vaccine development. Curr Opin Virol 2020;44:191-202. [PMID: 33254031 DOI: 10.1016/j.coviro.2020.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|